Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography

Europace. 2016 Oct;18(10):1599-1607. doi: 10.1093/europace/euv380. Epub 2015 Dec 24.

Abstract

Aims: Spontaneous Ca2+ release leads to afterdepolarizations and triggered arrhythmia in catecholaminergic polymorphic ventricular tachycardia (CPVT). Irregular Ca2+ release is hypothesized to manifest as slowed depolarization and irregular repolarization. Our goal was to study depolarization and repolarization abnormalities in CPVT, as they remain largely uninvestigated.

Methods and results: We studied intracellular Ca2+ handling and action potentials (APs) in an induced pluripotent stem cell (iPSC) model of CPVT. Induced pluripotent stem cell cardiomyocytes from a RyR2-P2328S patient showed increased non-alternating variability of Ca2+ transients in response to isoproterenol. β-Agonists decreased AP upslope velocity in CPVT cells and in monophasic AP recordings of CPVT patients. We compared 24 h electrocardiograms (ECGs) of 19 CPVT patients carrying RyR2 mutations and 19 healthy controls. Short-term variability (STV) of the QT interval was 6.9 ± 0.5 ms in CPVT patients vs. 5.5 ± 0.4 ms in controls (P < 0.05) and associated with a history of arrhythmic events. Mean T-wave alternans (TWA) was 25 ± 1.4 µV in CPVT patients vs. 31 ± 2.0 µV in controls (P < 0.05). Older CPVT patients showed lower maximal upslope velocity of the ECG R-spike than control patients.

Conclusion: Catecholaminergic polymorphic ventricular tachycardia patients show higher STV of repolarization but lower TWA on the 24 h ECG than control patients, which is likely to reflect increased non-alternating variability of Ca2+ release by mutant RyR2s as observed in vitro. β-Agonists slow depolarization in RyR2-mutant cells and in CPVT patients. These findings may constitute a marker of arrhythmogenicity.

Keywords: Alternans; Calcium; Catecholaminergic polymorphic ventricular tachycardia; Ryanodine receptor; Variability.

MeSH terms

  • Action Potentials*
  • Adrenergic beta-Agonists / therapeutic use
  • Adult
  • Calcium Signaling*
  • Case-Control Studies
  • Electrocardiography, Ambulatory
  • Female
  • Finland
  • Humans
  • Induced Pluripotent Stem Cells / cytology
  • Isoproterenol / therapeutic use
  • Male
  • Middle Aged
  • Mutation
  • Myocytes, Cardiac / cytology*
  • Ryanodine Receptor Calcium Release Channel / genetics
  • Tachycardia, Ventricular / genetics
  • Tachycardia, Ventricular / physiopathology*

Substances

  • Adrenergic beta-Agonists
  • RyR2 protein, human
  • Ryanodine Receptor Calcium Release Channel
  • Isoproterenol

Supplementary concepts

  • Polymorphic catecholergic ventricular tachycardia